Volume LVII, Number 1
Krishna B Bhadriraju
Jenks High School
Saint Francis Health System
Mani Cheruvu, PhD*
Saint Francis Health System
Introduction
In this era of evidence-based medicine, clinical trials are considered the gold standard for determining optimal patient treatment. As the research landscape evolves, multi-site and multinational clinical trials have become increasingly prevalent compared to conventional single-site studies (Lang & Siribaddana, 2012; Drain et al., 2014). While organizations such as the World Health Organization (WHO; https://www.who.int/) have published best-practice guidance structured around core themes, including the importance of trials, persistent challenges, key scientific and ethical considerations, transformation and ecosystem strengthening, a similarly comprehensive and all-encompassing framework specifically for Global Clinical Trials (GCTs) is still lacking.
A GCT is defined as any clinical trial conducted as part of a multinational development program to assess the efficacy and safety of new drugs or devices across varied populations. By ensuring diverse representation, these trials confirm that findings are applicable to a broad demographic spectrum. Furthermore, because data is aggregated from diverse sites worldwide, GCTs generate the high-quality, reliable evidence essential for informing health policy and clinical practice.
Despite their numerous advantages, GCTs face a unique set of challenges that can impede their success and affect data reliability. To better understand the impact of both intrinsic and extrinsic factors on these studies, we performed a Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis. A SWOT analysis is a realistic, fact-based, data-driven review to define an entity’s competitive position, assess internal and external issues, and evaluate its current and future potential (https://www.eda.gov/resources/comprehensive-economic-development-strategy/content/swot-analysis). While SWOT analysis is a fact-based planning tool traditionally used to define an organization's competitive position, its utility in evaluating the GCT ecosystem is significant. In this article, we strategically examine the resources that make GCTs competitive and relevant in clinical research while identifying critical areas for improvement to maximize efficiency and achieve their full potential.
Strengths
Because GCTs span multiple global regions, the enrolled patient population is inherently more diverse. This diversity is instrumental in understanding how investigational drugs or devices perform across different ethnicities and geographical distributions. Furthermore, GCTs offer the distinct advantage of rapid recruitment; by accessing a larger pool of participants, enrollment targets are met more quickly, allowing primary endpoints to be reached and results to be analyzed sooner. This accelerated timeline can significantly reduce overall research and development (R&D) expenditures, as clinical trial costs typically represent a substantial portion of annual R&D budgets (Garnier, 2008; Li et al., 2015).
The results derived from GCTs benefit the global population, making these trials exceptionally important during and after pandemics. They provide critical insights into diverse patient populations, varying environmental factors, and the complex interactions between different host dynamics and viral or bacterial pathogens (Ferdinand & Igari, 2018).
Weaknesses
One significant risk in GCTs is the potential for investigators and sponsors to exploit the social, economic, psychological, or cultural vulnerabilities of participants in specific regions. Certain nations may be targeted due to weaker socioeconomic backgrounds, which can lead to a skewed risk-benefit analysis. For instance, inherent biases may arise if investigators prioritize high enrollment numbers by offering financial incentives that, while modest by international standards, are disproportionately influential in the host country. Furthermore, cultural disadvantages, including language barriers and low literacy rates, can compromise adherence to Good Clinical Practice (GCP), particularly during the informed consent process.
Additionally, countries with regulatory frameworks that do not align with international standards may be more susceptible to sponsor or investigator targeting, potentially leading to the exploitation of patient populations. Such ethical lapses often result in long-term challenges with recruitment and participant retention. Furthermore, inconsistent regulatory oversight complicates the reporting of adverse events, raising critical questions regarding the integrity of safety monitoring. Finally, the use of subjective tools, such as Quality-of-Life (QoL) questionnaires, and varying interpretations of terms like "standard of care" across different regions can introduce unintended biases, further complicating data synthesis, in addition to intrinsic ethnic differences (Asano et al., 2013).
Opportunities
Although international frameworks such as the International Council for Harmonization (ICH) and GCP serve as foundational guides, regulatory standards continue to vary significantly between nations. The increasing prevalence of GCTs provides international regulators with the necessary momentum to develop and establish more comprehensive, universal regulatory guidelines (Dixit et al., 2025). Furthermore, the shared research frameworks, pooled resources, and global expertise inherent in GCTs foster new collaborations. These partnerships expand research logistics, leading to more rigorous, evidence-based data generation and enhanced global data-sharing practices. GCTs also present unique opportunities for studying rare diseases; by operating on a global scale, researchers can overcome the recruitment challenges posed by limited local patient populations.
For emerging economies, particularly those with a strong historical risk aversion toward clinical research, participation in GCTs can help streamline risk-management processes. Engaging in these global efforts allows such countries to build the necessary infrastructure to become competitive with developed markets. Ultimately, this integration facilitates their participation in upcoming trials for innovative drugs and medical devices, ensuring that medical advancement is a truly global endeavor (Dixit et al., 2025).
Threats
A primary concern in GCTs is the potentially inequitable distribution of research benefits and burdens across different regions. While ethical standards mandate balance, the experience of a participant in a developed nation can differ vastly from that of one in a developing country. For instance, in a placebo-controlled trial for a disease with low local prevalence, participants in the placebo arm from a developing nation may receive no direct clinical benefit, potentially receiving only a financial incentive. This imbalance risks violating the "Justice" principle of the Belmont Report. Furthermore, the risk-benefit ratio is highly contextual; an intervention deemed too risky in a society where a disease is rare might have a favorable profile in a high-burden region. For example, a tuberculosis vaccine trial yields significantly higher social and individual utility when conducted in high-burden regions, such as parts of Africa, compared to low-burden nations like the United States (Wright et al., 2024).
Public perception also poses a significant threat (Anderson et al., 2018). In certain regions, industry-sponsored research is viewed with skepticism, with sponsors perceived as profiting at the expense of vulnerable populations. Such mistrust can lead to a categorical rejection of GCT participation and the resulting data, ultimately hindering the delivery of effective therapies to those specific populations.
Finally, financial and systemic barriers present substantial hurdles. Insurance coverage for "standard of care" procedures varies wildly between countries, often leaving participants uncertain of their potential out-of-pocket costs. This financial ambiguity can impede recruitment, diminish retention, and compromise individualized care. Moreover, there is a risk that third-party payers may use trial participation as a justification for increasing premiums, further exacerbating health disparities between developed and developing nations.
Conclusion
In summary, while the medical insights derived from GCTs are undoubtedly vital, the complexities of operating across diverse regulatory, technical, cultural, and socioeconomic landscapes persist. These challenges coexist with significant opportunities and threats, as illustrated in the SWOT analysis summarized in Figure 1. The current GCT regulatory framework, while essential, remains inadequate for the scale of modern research. Consequently, there is an urgent need for a more comprehensive, inclusive, and globally coherent framework.
Figure 1. SWOT Analysis of Global Clinical Trials
At this critical juncture, the efforts of the WHO in launching the Global Clinical Trials Forum (GCTF) are commendable. The GCTF serves as a multi-stakeholder network designed to strengthen clinical trial environments and infrastructure at national, regional, and global levels. By uniting a diverse array of stakeholders, including member states, regulators, ethics authorities, funders, researchers, civil society, and patient organizations, the GCTF provides a collaborative platform to disseminate WHO guidance, advocate for the adoption of international standards, and share knowledge to advance ethical and impactful clinical research (World Health Organization, 2025).
Ultimately, human research ethics must remain at the forefront of the GCT discourse, particularly as trial designs grow in complexity. Addressing these challenges in a fair, balanced, and transparent manner, with an unwavering commitment to protecting the most vulnerable participants, will ensure the development of rigorous GCTs. Such efforts will likely yield higher success rates and provide greater health benefits for the global community.
Authors’ Note
The views expressed in the article are those of the authors alone and do not necessarily reflect the views of the authors’ employer, company, Institution, or other associated parties.
Krishna B Bhadriraju
Jenks High School 205 E B St, Jenks, OK 74037
Volunteer, Saint Francis Health System
6161 S Yale Avenue, Tulsa, OK 74136
Mani Cheruvu, PhD*
System Director, Graduate Medical Education
Research and Sponsored Programs, Saint Francis Health System
6161 S Yale Avenue, Tulsa, OK 74136
Correspondence concerning this article should be addressed to mani.cheruvu@gmail.com.
References
Anderson, A., Borfitz, D., & Getz, K. (2018). Global public attitudes about clinical research and patient experiences with clinical trials. JAMA Network Open, 1(6), e182969. https://doi.org/10.1001/jamanetworkopen.2018.2969
Asano, K., Tanaka, A., Sato, T., & Uyama, Y. (2013). Regulatory challenges in the review of data from global clinical trials: The PMDA perspective. Clinical Pharmacology & Therapeutics, 94(2), 195-198. https://doi.org/10.1038/clpt.2013.106
Dixit, S., Sharma, N., & Shukla, V. K. (2025). Systematic review on clinical trial regulations: Perspectives from India, USA, and Europe. Reviews on Recent Clinical Trials. Epub ahead of print. https://doi.org/10.2174/0115748871365163250707075747
Drain, P. K., Robine, M., Holmes, K. K., & Bassett, I. V. (2014). Trial watch: Global migration of clinical trials. Nature Reviews Drug Discovery, 13(3), 166-167. https://doi.org/10.1038/nrd4260
Ferdinand, K. C., & Igari, M. (2018). The role of racial/ethnic factors in global clinical trials. Expert Review of Clinical Pharmacology, 11(9), 829-832. https://doi.org/10.1080/17512433.2018.1510311
Garnier, J. P. (2008). Rebuilding the R&D engine in big pharma. Harvard Business Review, 86(5), 68-70. https://hbr.org/2008/05/rebuilding-the-rd-engine-in-big-pharma
Lang, T., & Siribaddana, S. (2012). Clinical trials have gone global: Is this a good thing? PLoS Medicine, 9(6), e1001228. https://doi.org/10.1371/journal.pmed.1001228
Li, R., Barnes, M., Aldinger, C. E., & Bierer, B. E. (2015, Spring). Global clinical trials: Ethics, harmonization and commitments to transparency. Harvard Public Health Review, 6, 1-7. https://www.jstor.org/stable/48503032
World Health Organization. (2025, October 7). WHO launches the Global Clinical Trials Forum. https://www.who.int/news/item/07-10-2025-who-launches-the-global-clinical-trials-forum
Wright, K., DeCormier Plosky, W., Ahmed, H. R., White, S. A., & Bierer, B. E. (2024). First, do no harm: A global perspective on diversity and inclusion in clinical trials. Nature Reviews Drug Discovery, 23(7), 481-482. https://doi.org/10.1038/d41573-024-00078-4